Chronic Thromboembolic Pulmonary Hypertension Due to Popliteal Vein Aneurysm.

BACKGROUND: Venous thromboembolism (VTE) may present acutely as pulmonary embolism (PE), and its late complications include chronic thromboembolic pulmonary hypertension (CTEPH). PEs may arise from thrombi originating in a venous aneurysm, in rare cases of the popliteal vein. CASE
PRESENTATION: A 77-year-old woman was referred to our hospital due to respiratory distress. Computed tomography revealed pulmonary thrombi and a thrombus in a popliteal vein aneurysm (PVA); PE was diagnosed. After 3 months of anticoagulant therapy (rivaroxaban), her pulmonary hypertension showed little improvement. She underwent perfusion scintigraphy, which showed multiple perfusion defects, and Swan-Ganz catheterization. Mean pulmonary artery pressure was 26 mmHg. Pulmonary angiography revealed organized distal thrombi. Based on these findings, we diagnosed CTEPH due to recurrent formation of thrombi in the PVA.
CONCLUSION: Asymptomatic PVA can lead silently to PE and CTEPH. The possibility of asymptomatic recurrent VTE should be considered in patients with pulmonary hypertension and PVA.

Introduction

Venous thromboembolism (VTE), manifesting as deep vein thrombosis (DVT) or pulmonary embolism (PE), is encountered in various clinical situations. It may present acutely as PE, which is potentially fatal, and its late complications include post-thrombotic syndrome and chronic thromboembolic pulmonary hypertension (CTEPH).1 Although only a small proportion (<4%) of patients with acute PE develop CTEPH,2,3 CTEPH is strongly associated with a history of VTE (PE and DVT in 75% and 56% of 679 patients whose data were included in an international prospective registry).4

Pulmonary embolism may arise from thrombi originating in a venous aneurysm (fusiform dilatation of a vein to at least twice its normal size). Large aneurysms carry an 80% risk of PE, even in cases in which anticoagulant therapy is given.5 Rarely, aneurysms develop in the popliteal vein. The causes of popliteal venous aneurysm (PVA) are unknown; however, congenital vein wall weakness, inflammation, and infection have been suggested as risk factors.6

Here, we describe a case of CTEPH due to asymptomatic PVA. To our knowledge, this is the first report of its kind.

Case Presentation

A woman aged 77 years was referred to our hospital due to respiratory distress. She had no medical history until then like hypertension, dyslipidemia or diabetes. And she also did not have any risk factors like thrombophilia, history of trauma, hospitalization steroids use, hormonal contraceptives, current smoking, chronic respiratory disease, infection, recent surgery, cancer and chemotherapy. Her blood pressure was 132/74 mmHg, she had a regular heart rate of 108 bpm and a respiratory rate of 18 breaths/min, and her oxygen saturation was 85% on room air. Electrocardiography showed inverted T waves in leads V1–3. Chest X-ray showed dilatation of the pulmonary artery and a cardiothoracic ratio of 60% (Figure 1).

Figure 1

Electrocardiography, chest X-Ray, and echocardiography before and after 12 weeks anticoagulant therapy (A and B).

Echocardiography showed right ventricular dilatation and a tricuspid regurgitation pressure gradient of 70 mmHg (Figure 1). Computed tomography (CT) revealed thrombotic occlusions of both pulmonary arteries and, coincidentally, a thrombus in an aneurysm in the popliteal vein of the left leg (Figures 2 and 3). Right to left ventricle (RV:LV) diameter ratio, measured on the four-chamber view, was high (2.11). Based on these findings, acute PE was diagnosed and the patient was started on rivaroxaban (15 mg orally twice daily for the first 21 days, followed by a maintenance dose of 20 mg orally once daily).

Figure 2

Thrombotic occlusion of pulmonary arteries and thrombus in the popliteal vein at first time and after 12 weeks anticoagulant therapy (A and B). Yellow arrows showed thrombus in pulmonary artery on computed tomography and showed thrombus in PVA on ultrasonography.

Figure 3

Perfusion scintigraphy, computed tomography, and CT angiography before and after 12 weeks anticoagulant therapy (A and B). Black arrow showed right ventricular dilatation. Yellow arrows showed thrombus (A) and popliteal vein aneurysm (B).

After 12 weeks of anticoagulant therapy, the thrombus in the popliteal vein aneurysm was disappeared (Figure 2). The D-dimer value had normalized (from 14.6 μg/mL to 0.5 μg/mL). CT angiography showed dissipation of the pulmonary thrombus, but RV:LV diameter ratio remained high (1.25). Perfusion scintigraphy showed that multiple perfusion defects remained (Figures 3 and 4). Swan–Ganz catheterization was also performed. Mean pulmonary artery pressure was 26 mmHg, and pulmonary vascular resistance, 6.65 Wood units. Pulmonary angiography revealed organized distal thrombi. Based on these findings, we diagnosed CTEPH due to recurrent formation of thrombi in the PVA.

Figure 4

Perfusion scintigraphy and pulmonary angiography after 12 weeks anticoagulant therapy. Chronic thrombus showed the perfusion defect on scintigraphy and pulmonary angiography. Yellow arrows showed the multiple chronic and organized thromboembolic obstructions in the distal part of the pulmonary arteries.

The patient is now due to undergo balloon pulmonary angioplasty (BPA) and surgery to treat the CTEPH and PVA, respectively.

Discussion

Standard medical treatment for CTEPH comprises anticoagulant therapy supplemented by diuretics and oxygen, as necessary. The guidelines of the European Society of Cardiology recommend anticoagulant therapy with a vitamin K antagonist (VKA).7 In cases in which the VKA fails to control CTEPH, and the potential benefits are judged to outweigh the risks, the patient can be switched to a DOAC.8 The preference for a VKA over a direct oral anticoagulant (DOAC) for treating CTEPH is based on decades of clinical experience with the former compared with limited experience with the latter.

In the case described here, the patient was initially started on a DOAC, rivaroxaban, to treat her acute PE. Several months later, when CTEPH had been diagnosed, we decided to continue anticoagulant therapy with rivaroxaban rather than change it to a VKA, because the patient’s clinical course was considered stable. Standard treatment for acute venous thromboembolism is limited by the need for parenteral heparin initially, with overlapping administration of a vitamin K antagonist. The relative efficacy and safety of rivaroxaban were similar to those of standard therapy in EINSTEIN program.9 So, we selected the rivaroxaban therapy in this case. But the efficacy of rivaroxaban therapy in CTEPH remains unclear. So, we decided to change standard therapy before BPA.

Evidence for DOAC has not yet been established in the CTEPH treatment. Now, powered multicenter prospective cohort studies with systematic, multimodality follow-up programs are needed to confirm the using DOAC for CTEPH. In this case, we might have better to change the standard VKA treatment earlier.

This case is an example of recurrent formation of thrombi in an asymptomatic PVA leading silently to PE and CTEPH.10 PVA is associated with a significant risk of fatal PE.2 In cases of CTEPH, timely therapeutic intervention greatly improves prognosis.11,12 Popliteal vein aneurysms >20 mm should be considered for surgical treatment or lifelong anticoagulation, depending on the patient’s preference. In this case, we planned surgery for resection of the popliteal vein aneurysm.13 The possibility of asymptomatic recurrent venous thromboembolism should be considered in patients with pulmonary hypertension and PVA.